MODULATION OF B-LYMPHOCYTE DIFFERENTIATION BY CALCITONIN-GENE-RELATED PEPTIDE (CGRP) .1. CHARACTERIZATION OF HIGH-AFFINITY CGRP RECEPTORS ON MURINE 70Z/3 CELLS

被引:35
作者
MCGILLIS, JP [1 ]
HUMPHREYS, S [1 ]
RANGNEKAR, V [1 ]
CIALLELLA, J [1 ]
机构
[1] UNIV KENTUCKY, COLL MED, SANDERS BROWN CTR AGING, LEXINGTON, KY 40536 USA
关键词
D O I
10.1006/cimm.1993.1207
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Calcitonin gene-related peptide (CGRP) is a 37-amino acid neuropeptide found in both peripheral and central neurons and in certain endocrine tissues. Previous studies have identified specific high-affinity CGRP receptors on normal T and B cells and have described modulatory effects of CGRP on freshly isolated lymphocytes. In these studies several lymphocyte cell lines were screened for 125I-CGRP binding. One cell line, the murine 70Z/3 pre-B cell line, was found to exhibit a high level of 125I-CGRP binding and was used for further characterization of the lymphocyte CGRP receptor. Several protease inhibitors were evaluated for their ability to stabilize 125I-CGRP binding to 70Z/3 cells. Bacitracin, a relatively nonspecific protease inhibitor, and chymostatin, a cysteine protease inhibitor, enhanced 125I-CGRP binding, suggesting that 70Z/3 cells express a protease capable of inactivating CGRP. 125I-CGRP binding had a linear dependence on cell concentration with binding being detectable with as few as 200,000 cells/ml and was rapid, with equilibrium binding being reached by 30 min. Saturation binding studies demonstrated that the 70Z/3 CGRP receptor has both low- and high-affinity binding states, with Kas of approximately 0.2 and 3.3 nM, respectively. The density of the low-affinity binding site was approximately 20,000 sites/cell and was unchanged following LPS treatment. In contrast, LPS treatment for 48 hr induced a fourfold increase in the density of the high-affinity site, from 105 to 401 sites/cell. In competition binding studies, only CGRP and the CGRP antagonist CGRP8.37 inhibited 125ICGRP binding, whereas the unrelated neuropeptides calcitonin, SP, and CRH had no effect. Inhibition of 125 I-CGRP binding by rat CGRP was best described by a two-site model, with Kis of 44.1 pM and 0.6 nM. Inhibition of binding by human CGRP and CGRP8-37 was best described by a one-site model with Kis of 3.92 and 6.50 nM, respectively. The 70Z/3 CGRP receptor protein was biochemically characterized by affinity labeling the receptor protein with 125I-CGRP and the covalent cross-linking reagents DSS or BS3. SDS-PAGE analysis revealed a major band of 103,000 MW. In addition a high-molecular-weight complex which did not penetrate the gel was also observed. The presence of CGRP receptors on 70Z/3 cells provides further evidence for the immunomodulatory role for CGRP and provides a model system for studying the cellular mechanisms of action of CGRP in modulating lymphocyte differentiation and function. © 1993 Academic Press. All rights reserved.
引用
收藏
页码:391 / 404
页数:14
相关论文
共 43 条
[1]   EXPRESSION BRAIN OF A MESSENGER-RNA ENCODING A NOVEL NEUROPEPTIDE HOMOLOGOUS TO CALCITONIN GENE-RELATED PEPTIDE [J].
AMARA, SG ;
ARRIZA, JL ;
LEFF, SE ;
SWANSON, LW ;
EVANS, RM ;
ROSENFELD, MG .
SCIENCE, 1985, 229 (4718) :1094-1097
[2]  
BJURHOLM A, 1991, INT ORTHOP, V15, P325
[3]   CALCITONIN GENE-RELATED PEPTIDE IS A POTENT VASODILATOR [J].
BRAIN, SD ;
WILLIAMS, TJ ;
TIPPINS, JR ;
MORRIS, HR ;
MACINTYRE, I .
NATURE, 1985, 313 (5997) :54-56
[4]  
BUCKLEY TL, 1991, J IMMUNOL, V146, P3424
[5]  
Bulloch K, 1991, PROG NEURENDOCRINIMM, V4, P186
[6]  
CASINI A, 1989, N-S ARCH PHARMACOL, V339, P354
[7]   CALCITONIN GENE-RELATED PEPTIDE RECEPTOR ANTAGONIST HUMAN CGRP-(8-37) [J].
CHIBA, T ;
YAMAGUCHI, A ;
YAMATANI, T ;
NAKAMURA, A ;
MORISHITA, T ;
INUI, T ;
FUKASE, M ;
NODA, T ;
FUJITA, T .
AMERICAN JOURNAL OF PHYSIOLOGY, 1989, 256 (02) :E331-E335
[8]   ENDOPEPTIDASE-24.11 CLEAVES A CHEMOTACTIC FACTOR FROM ALPHA-CALCITONIN GENE-RELATED PEPTIDE [J].
DAVIES, D ;
MEDEIROS, MS ;
KEEN, J ;
TURNER, AJ ;
HAYNES, LW .
BIOCHEMICAL PHARMACOLOGY, 1992, 43 (08) :1753-1756
[9]  
DENNIS T, 1989, J PHARMACOL EXP THER, V251, P718
[10]  
GOLDMAN DW, 1982, J IMMUNOL, V129, P1600